Scholar Rock received FDA approval for ISEMBYLD, the first muscle-targeted therapy for spinal muscular atrophy (SMA), aimed at patients aged two and older already on other treatments. The drug is priced at $11,659 per vial and has earned a Rare Pediatric Disease Priority Review Voucher. Following this milestone, Jefferies raised Scholar Rock's price target from $57 to $65, reflecting optimism about the company's growth potential. The stock traded at $51.85 with a market cap of about $6.21 billion at the time of the update.
Scholar Rock's recent FDA approval news is presented here with Pluang's health sector market data as of Sep 15, 2026 19:14 WIB: Among 91 priced US health stocks, 28 rose and 59 fell. Notable movers include AMWL at USD 13.66 with a -1.51% change, HRTX at USD 0.32 with a +1.49% change, and CNC at USD 68.40 with a -1.41% change.
Ascendis Pharma A/S regained full control of its TransCon technology for metabolic diseases from Novo Nordisk, allowing it to independently develop and sell treatments, including for obesity. The company also authorized a $400 million share repurchas...
Tesla's US market share has recovered to 52% after a sharp decline in 2025 linked to CEO Elon Musk's political ties, which hurt brand loyalty and wiped out over $500 billion in market value. While overall US EV sales dropped 30% through August 2026, ...
Oracle's stock has fallen over 52% in the past year but is expected to recover strongly, with Mizuho Securities predicting a 121% rise to $320 in the next 12 months. This optimism is driven by accelerating cloud infrastructure growth and disciplined ...
Elon Musk and Jim Cramer both suspect that AI doom warnings from leading labs are motivated by commercial interests. Musk proposes a peer-review safety system where AI companies test each other's models to prevent harmful behavior, emphasizing the ne...
The Solana Foundation has introduced Frontier Traders, a rewards program that tracks trading activity across 16 venues and offers VIP benefits to high-volume professional traders, including market makers and hedge funds. The program features tiered r...
